Stock ESPR ESPERION THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Relative Strength Chart Esperion Therapeutics, Inc.

Equities

ESPR

US29664W1053

Market Closed - Nasdaq
Other stock markets
 03:59:48 2024-06-04 pm EDT 		5-day change 1st Jan Change
2.25 USD +0.45% Intraday chart for Esperion Therapeutics, Inc. +7.14% -24.75%
May. 22 Daiichi Sankyo Europe GmbH and Esperion Therapeutics, Inc. Jointly Announce That European Commission Has Approved the Label Update of Both NILEMDO® (bempedoic acid) and NUSTENDI® (bempedoic acid / ezetimibe fixed-dose combination), as Treatments for Hypercholesterolemia and to Reduce the Risk of Adverse Cardiovascular Events CI
May. 20 Esperion Therapeutics Says Primary Endpoint Achieved in Hypercholesterolemia Treatment Phase 3 Trial; Shares Rise MT

End-of-day quotes

Compared values

Sector Change 5d. change 1st Jan change 1-year change 5-years change Capi. ST MT LT
ESPERION THERAPEUTICS, INC.
Other Pharmaceuticals
+0.45%+7.14%-24.75%+65.44%-95.51% 426M
Neutral
Neutral
Bullish
  1. Stock Market
  2. Equities
  3. ESPR Stock
  4. Charts Esperion Therapeutics, Inc.
  5. Relative Strength Chart